Literature DB >> 11304516

Angiotensin-(1-7) downregulates the angiotensin II type 1 receptor in vascular smooth muscle cells.

M A Clark1, D I Diz, E A Tallant.   

Abstract

Angiotensin (Ang)-(1-7) is a biologically active peptide of the renin-angiotensin system that has both vasodilatory and antiproliferative activities that are opposite the constrictive and proliferative effects of angiotensin II (Ang II). We studied the actions of Ang-(1-7) on the Ang II type 1 (AT(1)) receptor in cultured rat aortic vascular smooth muscle cells to determine whether the effects of Ang-(1-7) are due to its regulation of the AT(1) receptor. Ang-(1-7) competed poorly for [(125)I]Ang II binding to the AT(1) receptor on vascular smooth muscle cells, with an IC(50) of 2.0 micromol/L compared with 1.9 nmol/L for Ang II. The pretreatment of vascular smooth muscle cells with Ang-(1-7) followed by treatment with acidic glycine to remove surface-bound peptide resulted in a significant decrease in [(125)I]Ang II binding; however, reduced Ang II binding was observed only at micromolar concentrations of Ang-(1-7). Scatchard analysis of vascular smooth muscle cells pretreated with 1 micromol/L Ang-(1-7) showed that the reduction in Ang II binding resulted from a loss of the total number of binding sites [B(max) 437.7+/-261.5 fmol/mg protein in Ang-(1-7)-pretreated cells compared with 607.5+/-301.2 fmol/mg protein in untreated cells, n=5, P<0.05] with no significant effect on the affinity of Ang II for the AT(1) receptor. Pretreatment with the AT(1) receptor antagonist L-158,809 blocked the reduction in [(125)I]Ang II binding by Ang-(1-7) or Ang II. Pretreatment of vascular smooth muscle cells with increasing concentrations of Ang-(1-7) reduced Ang II-stimulated phospholipase C activity; however, the decrease was significant (81.2+/-6.4%, P<0.01, n=5) only at 1 micromol/L Ang-(1-7). These results demonstrate that pharmacological concentrations of Ang-(1-7) in the micromolar range cause a modest downregulation of the AT(1) receptor on vascular cells and a reduction in Ang II-stimulated phospholipase C activity. Because the antiproliferative and vasodilatory effects of Ang-(1-7) are observed at nanomolar concentrations of the heptapeptide, these responses to Ang-(1-7) cannot be explained by competition of Ang-(1-7) at the AT(1) receptor or Ang-(1-7)-mediated downregulation of the vascular AT(1) receptor.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11304516     DOI: 10.1161/01.hyp.37.4.1141

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  24 in total

Review 1.  New physiological concepts of the renin-angiotensin system from the investigation of precursors and products of angiotensin I metabolism.

Authors:  Carlos M Ferrario
Journal:  Hypertension       Date:  2009-12-21       Impact factor: 10.190

2.  Suppressing inflammation by inhibiting the NF-κB pathway contributes to the neuroprotective effect of angiotensin-(1-7) in rats with permanent cerebral ischaemia.

Authors:  Teng Jiang; Li Gao; Jun Guo; Jie Lu; Yao Wang; Yingdong Zhang
Journal:  Br J Pharmacol       Date:  2012-12       Impact factor: 8.739

Review 3.  Role of angiotensin modulation in primary headaches.

Authors:  Erling Tronvik; Lars Jacob Stovner
Journal:  Curr Pain Headache Rep       Date:  2014-05

4.  Aging, Angiotensin system and dopaminergic degeneration in the substantia nigra.

Authors:  Jose L Labandeira-Garcia; Jannette Rodriguez-Pallares; Begoña Villar-Cheda; Ana I Rodríguez-Perez; Pablo Garrido-Gil; Maria J Guerra
Journal:  Aging Dis       Date:  2011-04-20       Impact factor: 6.745

Review 5.  ACE2/ANG-(1-7)/Mas pathway in the brain: the axis of good.

Authors:  Ping Xu; Srinivas Sriramula; Eric Lazartigues
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2010-12-22       Impact factor: 3.619

6.  The angiotensin-converting enzyme 2/angiogenesis-(1-7)/Mas axis confers cardiopulmonary protection against lung fibrosis and pulmonary hypertension.

Authors:  Vinayak Shenoy; Anderson J Ferreira; Yanfei Qi; Rodrigo A Fraga-Silva; Carlos Díez-Freire; Autumn Dooies; Joo Yun Jun; Srinivas Sriramula; Nithya Mariappan; Dorna Pourang; Changaram S Venugopal; Joseph Francis; Timothy Reudelhuber; Robson A Santos; Jawaharlal M Patel; Mohan K Raizada; Michael J Katovich
Journal:  Am J Respir Crit Care Med       Date:  2010-06-25       Impact factor: 21.405

7.  Inhibition of angiotensin-converting enzyme 2 exacerbates cardiac hypertrophy and fibrosis in Ren-2 hypertensive rats.

Authors:  Aaron J Trask; Leanne Groban; Brian M Westwood; Jasmina Varagic; Detlev Ganten; Patricia E Gallagher; Mark C Chappell; Carlos M Ferrario
Journal:  Am J Hypertens       Date:  2010-03-18       Impact factor: 2.689

8.  Brain angiotensin and dopaminergic degeneration: relevance to Parkinson's disease.

Authors:  Jose L Labandeira-Garcia; Jannette Rodriguez-Pallares; Ana I Rodríguez-Perez; Pablo Garrido-Gil; Begoña Villar-Cheda; Rita Valenzuela; Maria J Guerra
Journal:  Am J Neurodegener Dis       Date:  2012-11-18

9.  Defects in cutaneous angiotensin-converting enzyme 2 and angiotensin-(1-7) production in postural tachycardia syndrome.

Authors:  Julian M Stewart; Anthony J Ocon; Debbie Clarke; Indu Taneja; Marvin S Medow
Journal:  Hypertension       Date:  2009-03-16       Impact factor: 10.190

10.  Dopaminergic degeneration is enhanced by chronic brain hypoperfusion and inhibited by angiotensin receptor blockage.

Authors:  Ana I Rodriguez-Perez; Antonio Dominguez-Meijide; Jose L Lanciego; Maria J Guerra; Jose L Labandeira-Garcia
Journal:  Age (Dordr)       Date:  2012-09-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.